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We have examined the role of protein kinase C (PKC) m the stimulation of protein synthesis by insulin using two complemental approaches. 
In the first, fibroblasts were pretreated with phorbol esters to down-regulate PKC. In these cells, the effects of insulin and of phorbol esters on 
protein synthesis were completely abolished, although serum still elicited an effect approaching that seen in control cells. Secondly, we used newly 
developed inhibitors of PKC which, again, blocked the effects of insulin and phorbol esters without greatly reducing the response to serum, Thus 
PKC apparently plays an important role in the stimulation of translation by insulin. 
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1. INTRODUCTION 
Insulin acutely stimulates protein synthesis at the 
level of mRNA translation in a wide variety of mam- 
malian cell types [l-3], this effect being exerted primar- 
ily on the process of peptide-chain initiation. However, 
the signal transduction mechanism(s) involved in this 
effect of insulin, and the translational components 
which are the targets for regulation by this hormone, 
remain poorly understood. Recently we have demon- 
strated that in Swiss 3T3 cells insulin rapidly activates 
an initiation factor termed eIF-2B [4], which plays a key 
role in regulating peptide-chain initiation by recycling 
the factor, eIF-2, which binds the initiator Met-tRNAi 
to the ribosome (reviewed in [5]). In this paper we wish 
to address another aspect of the control of translation 
by insulin, viz. the role of protein kinase C (PKC) in the 
stimulation of protein synthesis by insulin. 
Several other research groups have studied the impor- 
tance of PKC in the intracellular actions of insulin. 
Work from Farese and colleagues upports such a role 
for PKC (see, e.g. [6-Q, although other workers have 
questioned this [9], as discussed in detail in [lo]. In the 
case of the stimulation of protein synthesis by insulin, 
two groups of workers have provided evidence for a role 
for PKC (reviewed in [l l]), based largely on the effects 
of down-regulation of PKC by long-term phorbol ester 
treatment, on the ability of insulin to stimulate either 
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overall protein synthesis or the phosphorylation of indi- 
vidual initiation factors [12-141. 
We have extended this work by examining the effects 
of a series of novel protein kinase C inhibitors (Ro-31- 
7549, Ro-3 l-8220, and Ro-3 l-8425) on the activation of 
protein synthesis by insulin and other stimuli in Swiss 
3T3 cells. These and related compounds have been 
shown to block effects believed to be mediated by PKC 
[15-171. Our data support the involvement of PKC in 
the stimulation of protein synthesis by insulin. 
2. MATERIALS AND METHODS 
2.1. ~aferju~s 
All materials were obtained as described in [4] unless otherwise 
indicated. The PKC inhibitors, Ro-31-7549, Ro-31-8220 and Ro-31- 
8425, were a generous gift from Dr J. Nixon, Roche Products Ltd., 
Welwyn Garden City, Herts, UK. The phorbol ester, PDBu, was 
purchased from Sigma Chemical Co. (Poole, Dorset. UK). Insulin 
receptors, which were partially purified from CH0.T cell extracts by 
wheat-germ lectin-Sepharose chromatography and concentrated as 
described previously [18], were a generous gift from Mr S. Young, 
Department of Biochemistry, University of Bristol. Anti-insulin recep- 
tor antibody, 83-7, was a kind gift from Professor K. Siddle (Univer- 
sity of Cambridge). 
2.2. Cell culture and protein syntfiesis assoys 
Swiss 3T3 fibroblasts were grown and maintains as described in 
[4]. Protein synthesis assays were carried out as described in 141;. The 
PKC inhibitors were added at the same time as insulin. For down- 
regulation studies the phorbol ester, PDBu, was added at a concentra- 
tion of 2 PM, 24 h before protein synthesis assays were carried out. 
The PDBu stock solution was dissolved in acetone whilst the PKC 
inhibitors were dissolved in 100% DMSO. At the final concentrations 
used in the protein synthesis assays none of these vehicles had an effect 
on control or insulin-stimulated rates of protein synthesis (data not 
shown). Controls contained appropriate amounts of these com- 
pounds. 
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2.3. Assays of insulin receptor, tyrosine krnase activity 
The inhibitor studies on the insulin receptor kinase were performed 
using the immune-capture method of Zhang et al. [19] and utilized the 
synthetic peptide, RRDIFETDYFRK (synthesized by Dr. G. 
Bloomberg, University of Bristol) which is a substrate for the insulin 
receptor kinase [20]. 
3. RESULTS 
3.1. Phorbol esters, insulin and protein synthesis 
As we have shown previously [4], the phorbol ester, 
PDBu, rapidly (within 5 min) increases the rate of pro- 
tein synthesis in Swiss 3T3 cells (in those experiments 
to 121 k 7% of control rates seen in serum-depleted 
cells). Dose-response data for the activation of protein 
synthesis by PDBu shows maximal stimulation with 
about 2 PM and a half-maximal response at about 100 
nM (data not shown). 
3.2. The effect of down-regulation of PKC on the stimu- 
lation of protein synthesis by insulin 
Total cellular levels of PKC can be down-regulated 
by prolonged exposure of cells to phorbol esters [21]. 
Treatment of Swiss 3T3 fibroblasts with 2pM PDBu for 
24 h led to the complete abolition of the stimulation of 
protein synthesis when the cells were re-challenged with 
these agents, consistent with the idea that stimulation 
of protein synthesis by phorbol esters is mediated by 
PKC. However, this pre-treatment had no effect on the 
control level of protein synthesis. In these phorbol ester- 
pretreated cells the effect of insulin on protein synthesis 
Untreated 
I 24h pretre;;ment 
PDBu 
Fig. 1. Effect of pretreatment of Swiss 3T3 cells with phorbol esters on protein synthesis and its stimulation by insulin and serum. The effects of 
insulin (I, 10 nM), serum (S, 10%) or PDBu (P, 2 PM) were studied m cells treated with PDBu (2 PM)) or carrier only (ethanol) for 24 h prior 
to measurement of protein synthesis as described m section 2. The results are given as means f S.D. from five independent experiments. 
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was completely abolished whereas the effect of 10% 
serum was only inhibited by about 15% (Fig. 1). 
The observation that phorbol ester pretreatment had 
no effect on control levels of protein synthesis, and only 
a partial effect on the response to serum, indicates that 
the inhibition of the insulin response is due to the loss 
of part of the insulin signalling pathway and is not a 
result of inhibition of all responses due to impaired cell 
viability, since protein synthesis is a good indicator of 
this parameter. The partial abolition of the stimulation 
of protein synthesis by serum may be due to the loss of 
the insulin component of this response, although other 
components may be lost under these conditions. Thus 
it seems as if there are multiple pathways by which 
protein synthesis can be activated, and, in the case of the 
some of the components of foetal calf serum, these path- 
ways do not involve PKC. 
3.3. Effects of the PKC inhibitors, Ro-31-7549, Ro-31- 
8220 and Ro-31-8425, on the stimulation of protein 
synthesis by insulin and serum 
As in the case of the down-regulation studies, the 
three inhibitors each completely abolished the stimula- 
tion of protein synthesis by insulin without affecting 
control rates of protein synthesis (Fig. 2). The K,‘s for 
this inhibition for all three inhibitors are very low 
(Table I), suggesting that they are exerting their effects 
via inhibition of PKC as these concentrations are com- 
parable to those obtained by Nixon et al. [16] for other 
processes in which PKC has been implicated, such as 
the inhibition of the PMA-induced phosphorylation of 
p47 in platelets (4.4, 0.7 and 0.4 PM for Ro-31-7549, 
Ro-3 l-8220 and Ro-3 l-8425, respectively) and the 
PDBu-induced CD3 down-regulation in T cells (3.1, 
0.5, and 0.6 PM for Ro-31-7549, Ro-31-8220 and Ro- 
60 
no addition 
Insulin 
Serum 
Fig. 2. Effect of PKC inhibitors, Ro-31-7549, Ro-31-8220 and Ro-31-8425, on the stimulation of protein synthesis by insulin. The effect of insulin 
(20 nM) and serum (10%) on protein synthesis in Swiss 3T3 cells treated at the same time with 1 PM of the PKC inhibitors, Ro-3 l-7549, Ro-3 I-8220 
or Ro-31-8425, for 20 min. The results are gtven as means f SD. from four independent experiments. 
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Table I 
K, @M) for inhibition by PKC inhibitors of the stimulation of protein 
synthesis by insulin 
Agent K, @M) for inhibition of stimula- 
tion of protein synthesis by insulin 
Ro-3 l-7549 7.00 f 1.1 
Ro-31-8220 0.50 f 0.13 
Ro-31-8425 0.40 f 0.15 
Protein synthesis was measured as described in section 2. Values rep- 
resent means + SD. for at least four independent experiments with at 
least eight inhibitor concentrations for each determination. The data 
were analyzed by non-linear least-squares analysis. 
31-8425, respectively). Although the potency of these 
inhibitors on the stimulation of protein synthesis by 
insulin is lower than for the inhibition of purified PKC 
in vitro [l&16], it is likely that this is a result of the 
higher cellular concentration of ATP compared to those 
used in in vitro assays, which leads to reduced potency 
of these compounds which are competitive inhibitors of 
PKC with respect to ATP. 
These inhibitors also completely blocked the stimula- 
tion of protein synthesis by phorbol esters (data not 
shown), but had only limited effects on the degree of 
stimulation by 10% serum (Fig. 2). These data support 
the idea that these compounds do not affect cell viability 
since there is no inhibition of control levels of protein 
synthesis and the cells still respond markedly to serum. 
Other compounds used as PKC inhibitors (e.g. sphin- 
gosine and staurosporine) have been reported to affect 
cell viability adversely [22]. Therefore the effects of the 
agents used here on a number of other parameters indic- 
ative of cell viability were also tested: the PKC-inhib- 
itors, Ro-31-7549, Ro-31-8220 and Ro-31-8425, were 
without effect on cell attachment, evaluated microscop- 
ically, or on Trypan blue exclusion, even after 90 min 
at a concentration of 10 ,uM, which is lO-20-times the 
concentration used in the protein synthesis experiments 
(Table II). 
3.4. Effect of the PKC inhibitors on eIF-2B activity 
We have previously shown that phorbol esters and 
insulin each activate eIF-2B in Swiss 3T3 cells [4]. We 
therefore examined the effect of the PKC inhibitors on 
the stimulation of eIF-2B by these two agents. The ef- 
fect of phorbol esters is presumably mediated by PKC: 
Ro-31-8220 and Ro-3 l-8425 (both at 1 PM) completely 
abolished the activation of eIF-2B by 2 PM PDBu (Fig. 
3) consistent with this idea. In contrast, both Ro-31- 
8425 and Ro-31-8220 were without effect on the stimu- 
lation of eIF-2B by insulin (Fig. 3). 
3.5. Effect of the PKC inhibitors, Ro-31-7.549, Ro-31- 
8220 and Ro-31-8425, on the insulin receptor, tyro- 
sine kinase 
Staurosporine is a very potent but non-specific pro- 
tein kinase inhibitor which has been shown also to in- 
hibit receptor tyrosine kinases [23,24]. As the inhibitors 
used here are structurally similar to staurosporine, it 
was clearly possible that they inhibited the insulin stim- 
ulation of protein synthesis, not by affecting PKC, but 
by inhibiting the insulin receptor, tyrosine kinase. The 
effects of these inhibitors on insulin receptor tyrosine 
kinase activity was measured in an in vitro assay. Al- 
though all these compounds could inhibit the receptor 
kinase, they only did so at much higher concentrations 
than those used in our protein synthesis studies (Table 
II). The K, for the inhibition of the insulin receptor 
kinase by Ro-31-7549 and Ro-31-8220 in vitro was lo- 
20-times the K, for the inhibition of protein synthesis by 
these compounds in vivo and over lOO-times that for 
Ro-31-8425 (Table II). Furthermore, the K,‘s for the in 
vivo inhibition of the insulin receptor kinase by these 
competitive inhibitors are likely to be significantly 
higher than those obtained in vitro, as is the case with 
Table II 
Effects of the PKC inhibitors on various cellular processes 
Agent Effect on cell 
attachment 
Effect on cell 
viability 
Effect on control 
levels of protein 
synthesis (% of 
untreated control) 
K, @M) insulin 
receptor kinase 
Staurosporine 
Ro31-7549 
Ro3 l-8220 
Ro31-8425 
Yes 
No 
No 
No 
Yes 
No 
No 
No 
74 f 5 
98 f 4 
101 f3 
lOOf 
n.d. 
15f 3 
4f 2 
200 f 11 
The effect of staurosporine, Ro31-7549, Ro31-8220 and Ro31-8425 on cell attachment and cell viability was evaluated microscopically and by 
Trypan blue exclusion, respectively, after treatment of the cells with 1OpM of each inhibitor for 90 min. The effect of the PKC inhibitors on control 
levels of protein synthesis was measured after treatment of the cells for 60 min with 10 ,uM of each inhibitor. Results are given as means f S.D. 
for three separate xperiments. The effect of the PKC inhibitors on the insulin receptor kinase was determined by measurement of inhibition of 
insulin-dependent phosphorylation of exogenous ubstrate. Values represent means + S.D. for at least three separate xperiments with a minimum 
of seven inhibitor concentrations for each determination. Data was analyzed by non-linear least-squares analysis. 
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q Insulin PDBu 
no addition Ro-31-8220 Ro-31-8425 
Fig. 3. Effect of PKC inhibitors, Ro-31-8220 and Ro-31-8425, on the stimulation of eIF-2B activity by insulin and PDBu. The effect of insulin 
(20 nM) and PDBu (2 PM) on the stimulation of eIF-2B activity in Swiss 3T3 cells treated either with no addition or at the same time with 1 PM 
of the PKC inhibitors, Ro-31-8220 or Ro-31-8425, for 20 min was examined. The results are given as means f S.D. from four independent 
experiments. 
their inhibition of PKC [16], since the in vivo concentra- 
tion of ATP is at least lo-fold higher than that used in 
the tyrosine kinase assays which was 0.25 mM. Thus, 
it seems unlikely that these inhibitors are working by 
inhibiting the insulin receptor, tyrosine kinase, although 
due to their hydrophobicity it is possible that they tend 
to become concentrated in the plasma membrane. The 
observation that the PKC inhibitors do not block the 
activation of eIF-2B by insulin provides evidence that 
in the intact cell they are not acting simply by inhibiting 
the function of the insulin receptor. 
4. DISCUSSION 
The results above describe the use of the new and 
potent PKC inhibitors, Ro-3 l-7549, Ro-3 l-8220 and 
Ro-31-8425, to investigate the role of PKC in the stim- 
ulation of protein synthesis by insulin. In contrast to 
other PKC inhibitors available, Ro-3 l-7549, Ro-3 l- 
8220 and Ro-3 l-8425 possess a much improved specific- 
ity for PKC compared to other protein kinases [16] and 
do not seem to have any effect on cell viability. In 
protein synthesis assays these compounds (at nanomo- 
lar concentrations) totally abolished the stimulation of 
translation by both insulin and phorbol esters, without 
affecting control levels of protein synthesis, making it 
likely that they are doing so by inhibiting PKC. The 
compounds have much lesser effects on the stimulation 
of protein synthesis by serum, indicating that the cells 
are still responsive to certain components of serum and 
that presumably the mechanisms by which these agents 
activate protein synthesis are independent of PKC. 
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The data obtained using these inhibitors, taken to- 
gether with the results from the phorbol ester down- 
regulation studies, support the hypothesis that PKC is 
involved in the stimulation of protein synthesis by insu- 
lin, although the possibility that these compounds in- 
hibit other still-uncharacterized protein kinases with 
PKC-like properties cannot be ruled out. The findings 
that down-regulation of PKC by prolonged treatment 
with phorbol esters or inhibition of PKC using Ro-31- 
7549, Ro-31-8220 and Ro-31-8425 totally abolished the 
insulin effect indicates that there is an essential PKC- 
dependent component in the stimulation of protein syn- 
thesis by insulin. However, the observations that phor- 
bol esters increase protein synthesis, but to a lesser ex- 
tent than insulin [4], and that the PKC inhibitors block 
the activation of eIF-2B by PDBu but not by insulin 
suggest that there is also an additional PKC-independ- 
ent pathway involved in the insulin response. These two 
pathways appear to be distinct but overlapping. The 
first (PKC-dependent) pathway is common to both 
phorbol esters and insulin. However, other routes also 
have to be taken to get the full insulin effect, although, 
if PKC is down-regulated or inhibited these other mech- 
anisms are not sufficient in themselves to bring about 
an increase in protein synthesis. Thus activation of PKC 
seems to be necessary but not sufficient o obtain the full 
stimulation of protein synthesis by insulin. 
Two further inferences can be drawn from these re- 
sults: firstly, activation of eIF-2B is not in itself suffi- 
cient for stimulation of overall protein synthesis and, 
secondly, as a corollary, there are other processes re- 
quired for the activation of translation by insulin which 
are PKC dependent. They could include, for example, 
the phosphorylation of the cap-binding initiation fac- 
tor, eIF-4E, which has been reported to be enhanced by 
insulin [25] in a PKC-dependent manner [14]. Phospho- 
rylation of eIF-4E appears to play an important positive 
role in the control of protein synthesis (reviewed in [5]). 
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